x
Breaking News
0

Incyte Corporation (INCY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Incyte's earnings

Delivery Method

Status

Add to/Remove from a Portfolio My Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
132.72 -4.47    -3.26%
27/07 - Closed. Currency in USD ( Disclaimer )
After Hours
132.90
+0.18
+0.14%
27/07
Type: Equity
Market: United States
ISIN: US45337C1027 
CUSIP: 45337C102
  • Volume: 1,512,324
  • Bid/Ask: 115.52 / 135.00
  • Day's Range: 131.82 - 139.59
START TRADING NOW
Incyte 132.72 -4.47 -3.26%

INCY Overview

 
Information about the Incyte Corporation Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close137.19
Day's Range131.82 - 139.59
Revenue1.23B
Open138.73
52 wk Range75.52 - 153.15
EPS - 0.54
Volume1,512,324
Market Cap27.18B
Dividend (Yield)0 (N/A)
Average Vol. (3m)1,720,091
P/E RatioN/A
Beta0.84
1-Year Change49.59%
Shares Outstanding204,774,409
Next Earnings DateAug 01, 2017

Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Neutral Sell Strong Sell Buy Buy
Technical Indicators Strong Buy Strong Sell Strong Sell Strong Buy Strong Buy
Summary Buy Strong Sell Strong Sell Strong Buy Strong Buy

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Harami Cross 1H Current
Engulfing Bearish 1D Current
Completed Patterns
Engulfing Bearish 5H 2 Jul 27, 2017 05:00AM
Engulfing Bearish 1M 3 Apr 17
Evening Doji Star 1M 3 Apr 17

Incyte Corporation News & Analysis

News


Incyte Corporation Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 132.72 115.52 135.00 1,512,324 -3.26% USD 27/07  
  Berlin 113.00 112.36 113.56 0 -2.59% EUR 08:22:00  
  Stuttgart 112.62 112.61 113.78 0 -0.78% EUR 08:29:00  
  Munich 113.55 112.35 113.55 0 -2.32% EUR 06:00:00  
  Vienna 117.130 0.000 0.000 0 0.00% EUR 27/07  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Amazon.com 1,046.00 1,083.31 1,040.18 -6.80 -0.65% 10.99M 27/07  
  Facebook 170.44 175.49 167.50 +4.83 +2.92% 68.91M 27/07  
  Apple 150.56 153.99 147.30 -2.90 -1.89% 32.48M 27/07  
  Tesla 334.46 347.50 326.29 -9.39 -2.73% 8.30M 27/07  
  Play Communications 35.93 36.09 35.40 +0.43 +1.21% 1.39M 08:45:00  
  Yes Bank 1,830.15 1,861.00 1,765.00 +44.30 +2.48% 7.43M 09:00:00  
  Lic Housing Finance 753.35 756.00 726.00 +16.20 +2.20% 3.26M 09:00:00  
  Reliance Capital 713.50 718.80 660.25 +54.00 +8.19% 11.65M 09:00:00  
  Adidas 193.30 193.70 188.93 +16.30 +9.21% 790.47K 09:01:33  
  Boeing 241.00 242.68 236.70 +7.55 +3.23% 10.86M 27/07  

Incyte Corporation Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

980

Equity Type

ORD

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) Start Trading
U.S. Commodity Futures Trading Commission (United States) $250 Start Trading

My Sentiments

Add your sentiment:
or
 
Members' Sentiments:
Bullish
50%
Bearish
50%

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post
Post also to:
1000
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post 1000
Please wait a minute before you try to comment again.
 
 
 
Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Add Chart to Comment
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email